Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan;
Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Anticancer Res. 2021 Mar;41(3):1539-1545. doi: 10.21873/anticanres.14913.
BACKGROUND/AIM: Nivolumab monotherapy for advanced/metastatic renal cell carcinoma (RCC) shows a survival benefit. The purpose of this study was to evaluate tumor responses to nivolumab in various metastatic and primary sites in patients with RCC.
We retrospectively reviewed 68 patients who underwent nivolumab monotherapy after one or more regimens of targeted therapy for advanced/metastatic RCC. The site-specific response was evaluated and progression-free survival was estimated.
The site-specific overall response rates (ORRs) were as follows: lung (36%), bone (5%), lymph node (33%), liver (50%), adrenal gland (29%), pancreas (33%), and brain (0%). The ORR of bone metastasis was significantly worse in comparison to lung and liver metastases (p=0.017, 0.008). The site-specific median progression-free survival times were as follows: lung (5.1 months), bone (not reached), lymph node (not reached), and liver (17.5 months).
Responses to nivolumab may vary depending on metastasized organs.
背景/目的：纳武利尤单抗单药治疗晚期/转移性肾细胞癌（RCC）显示出生存获益。本研究的目的是评估纳武利尤单抗在接受过一种或多种靶向治疗方案的晚期/转移性 RCC 患者的各种转移和原发部位的肿瘤反应。
我们回顾性分析了 68 例接受纳武利尤单抗单药治疗的患者，这些患者在接受纳武利尤单抗单药治疗之前已经接受了一种或多种靶向治疗方案。评估了肿瘤特异性反应并估计了无进展生存期。
肿瘤特异性总体缓解率（ORR）如下：肺（36%）、骨（5%）、淋巴结（33%）、肝（50%）、肾上腺（29%）、胰腺（33%）和脑（0%）。与肺和肝转移相比，骨转移的 ORR 显著更差（p=0.017，0.008）。肿瘤特异性中位无进展生存期如下：肺（5.1 个月）、骨（未达到）、淋巴结（未达到）和肝（17.5 个月）。
对纳武利尤单抗的反应可能因转移器官而异。
